Eosinophilic Folliculitis Medication

  • Author: Camila K Janniger, MD; Chief Editor: Michael Stuart Bronze, MD   more...
 
Updated: May 2, 2011
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Next

Corticosteroids

Class Summary

These agents have both anti-inflammatory (glucocorticoid) and salt-retaining (mineralocorticoid) properties. Glucocorticoids have profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.

View full drug information

Prednisone (Sterapred)

 

May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Previous
Next

Retinoids

Class Summary

These agents decrease cohesiveness of abnormal hyperproliferative keratinocytes and may reduce potential for malignant degeneration. They modulate keratinocyte differentiation. They also reduce the risk of skin cancer in patients who have undergone renal transplant.

View full drug information

Isotretinoin (Accutane)

 

Retinoid acid derivative reduces size of sebaceous gland and decreases sebum production. Also regulates cell differentiation and proliferation.

Previous
Next

Nonsteroidal anti-inflammatory agents (NSAIDs)

Class Summary

These agents have analgesic, anti-inflammatory, and antipyretic activities. The mechanism of action is not known but may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may also exist (eg, inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, various cell-membrane functions).

View full drug information

Indomethacin (Indocin, Indochron ER)

 

Rapidly absorbed; metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation; inhibits prostaglandin synthesis.

Previous
Next

Antibiotics, sulfone; Leprostatic agents

Class Summary

These agents may improve the clinical stage of the disease.

View full drug information

Dapsone (Avlosulfon)

 

Bactericidal and bacteriostatic against mycobacteria; mechanism of action is similar to that of sulfonamides in which competitive antagonists of PABA prevent formation of folic acid, thus inhibiting bacterial growth.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Camila K Janniger, MD  Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Coauthor(s)

Rajendra Kapila, MD, MBBS  Professor of Medicine, Department of Medicine, UMDNJ, New Jersey Medical School

Rajendra Kapila, MD, MBBS is a member of the following medical societies: American College of Physicians, American Medical Association, Infectious Diseases Society of America, and Infectious Diseases Society of New Jersey

Disclosure: Nothing to disclose.

M Angelica Selim, MD  Associate Director of Dermatopathology, Departments of Pathology and Internal Medicine, Assistant Professor, Duke University Medical Center

Disclosure: Nothing to disclose.

Christopher R Shea, MD  Professor and Chief, Section of Dermatology, Department of Medicine, University of Chicago, The Pritzker School of Medicine

Christopher R Shea, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society of Dermatopathology, Arthur Purdy Stout Society, Association of Professors of Dermatology, Chicago Dermatological Society, Dermatology Foundation, Illinois Dermatological Society, International Society of Dermatopathology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Joseph Richard Masci, MD  Professor of Medicine, Professor of Preventive Medicine, Mount Sinai School of Medicine; Director of Medicine, Elmhurst Hospital Center

Joseph Richard Masci, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, Association of Professors of Medicine, and Royal Society of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Joseph F John Jr, MD, FACP, FIDSA, FSHEA  Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Eleftherios Mylonakis, MD  Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital

Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD  Professor, Stewart G Wolf Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Association of Professors of Medicine, Association of Program Directors in Internal Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

References

  1. Ise S, Ofuji S. Subcorneal pustular dermatosis. A follicular variant?. Arch Dermatol. Aug 1965;92(2):169-71. [Medline].

  2. Ofuji S, Ogino A, Horio T, et al. Eosinophilic pustular folliculitis. Acta Derm Venereol. 1970;50(3):195-203. [Medline].

  3. Nervi SJ, Schwartz RA, Dmochowski M. Eosinophilic pustular folliculitis: a 40 year retrospect. J Am Acad Dermatol. Aug 2006;55(2):285-9. [Medline].

  4. Suresh MS, Arora S, Nair RR. Doctor I am on fire: eosinophilic folliculitis in HIV negative. Indian J Dermatol Venereol Leprol. Mar-Apr 2009;75(2):194-6. [Medline].

  5. Fraser SJ, Benton EC, Roddie PH, Krajewski AS, Goodlad JR. Eosinophilic folliculitis: an important differential diagnosis after allogeneic bone-marrow transplant. Clin Exp Dermatol. Apr 2009;34(3):369-71. [Medline].

  6. Scavo S, Magro G, Caltabiano R. Erythematous and edematous eruption of the face. Eosinophilic pustular folliculitis. Int J Dermatol. Sep 2010;49(9):975-7. [Medline].

  7. Tsuboi H, Niiyama S, Katsuoka K. Eosinophilic pustular folliculitis (Ofuji disease) manifested as pustules on the palms and soles. Cutis. Aug 2004;74(2):107-10. [Medline].

  8. Sufyan W, Tan KB, Wong ST, et al. Eosinophilic pustular folliculitis. Arch Pathol Lab Med. Oct 2007;131(10):1598-601. [Medline].

  9. Brenner S, Wolf R, Ophir J. Eosinophilic pustular folliculitis: a sterile folliculitis of unknown cause?. J Am Acad Dermatol. Aug 1994;31(2 Pt 1):210-2. [Medline].

  10. Veraldi S, Ferrante P, Mancuso R, et al. Evidence of retroviral involvement in an Italian patient with Ofuji's disease. Dermatology. 1999;198(1):86-9. [Medline].

  11. Gul U, Kilic A, Demiriz M. Eosinophilic pustular folliculitis: the first case associated with hepatitis C virus. J Dermatol. Jun 2007;34(6):397-9. [Medline].

  12. Patrizi A, Chieregato C, Visani G, et al. Leukaemia-associated eosinophilic folliculitis (Ofuji's disease). J Eur Acad Dermatol Venereol. Sep 2004;18(5):596-8. [Medline].

  13. Kimoto M, Ishihara S, Konohana A. Eosinophilic pustular folliculitis with polycythemia vera. Dermatology. 2005;210(3):239-40. [Medline].

  14. Goiriz R, Guhl-Millan G, Penas PF, et al. Eosinophilic folliculitis following allogeneic peripheral blood stem cell transplantation: case report and review. J Cutan Pathol. Dec 2007;34 Suppl 1:33-6. [Medline].

  15. Boone SL, Guitart J, Gerami P. Follicular mycosis fungoides: a histopathologic, immunohistochemical, and genotypic review. G Ital Dermatol Venereol. Dec 2008;143(6):409-14. [Medline].

  16. Satoh T, Ito Y, Miyagishi C, Yokozeki H. Basophils Infiltrate Skin Lesions of Eosinophilic Pustular Folliculitis (Ofuji's Disease). Acta Derm Venereol. Jan 31 2011;[Medline].

  17. Annam V, Yelikar BR, Inamadar AC, Palit A, Arathi P. Clinicopathological study of itchy folliculitis in HIV-infected patients. Indian J Dermatol Venereol Leprol. May-Jun 2010;76(3):259-62. [Medline].

  18. Satoh T, Shimura C, Miyagishi C, Yokozeki H. Indomethacin-induced reduction in CRTH2 in eosinophilic pustular folliculitis (Ofuji's disease): a proposed mechanism of action. Acta Derm Venereol. 2010;90(1):18-22. [Medline].

  19. Fukamachi S, Kabashima K, Sugita K, Kobayashi M, Tokura Y. Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis. Acta Derm Venereol. 2009;89(2):155-9. [Medline].

  20. Otsuka A, Doi H, Miyachi Y, Kabashima K. Treatment of eosinophilic pustular folliculitis with ciclosporin: suppression of mRNA expression of IL-4 and IL-13. J Eur Acad Dermatol Venereol. Dec 2010;24(12):1489-91. [Medline].

  21. Lim HW, Vallurupalli S, Meola T, et al. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol. Sep 1997;37(3 Pt 1):414-7. [Medline].

  22. Misago N, Narisawa Y, Matsubara S, et al. HIV-associated eosinophilic pustular folliculitis: successful treatment of a Japanese patient with UVB phototherapy. J Dermatol. Mar 1998;25(3):178-84. [Medline].

  23. Hara D, Kuroda K, Mieno H, et al. Treatment of eosinophilic pustular folliculitis with tacrolimus ointment. J Am Acad Dermatol. Nov 2004;51(5 Suppl):S143-5. [Medline].

  24. Kabashima K, Sakurai T, Miyachi Y. Treatment of eosinophilic pustular folliculitis (Ofuji's disease) with tacrolimus ointment. Br J Dermatol. Oct 2004;151(4):949-50. [Medline].

  25. Kawaguchi M, Mitsuhashi Y, Kondo S. Successful treatment of eosinophilic pustular folliculitis with topical tacrolimus. Int J Dermatol. Aug 2004;43(8):608-10. [Medline].

  26. Brazzelli V, Barbagallo T, Prestinari F, et al. HIV seronegative eosinophilic pustular folliculitis successfully treated with doxicycline. J Eur Acad Dermatol Venereol. Jul 2004;18(4):467-70. [Medline].

  27. Wilson BD, Kucera JC, Shin PJ. The role of radiation treatment in the management of eosinophilic pustular folliculitis. J Med. 2002;33(1-4):111-3. [Medline].

  28. Basarab T. HIV-associated eosinophilic pustular folliculitis. J Am Acad Dermatol. Oct 1997;37(4):670-1. [Medline].

  29. Boudaya S, Turki H, Bouassida S, et al. [Eosinophilic pustular folliculitis in infancy: an unusual case]. Ann Dermatol Venereol. Apr 2003;130(4):451-4. [Medline].

  30. Buezo GF, Fraga J, Abajo P, et al. HIV-Associated eosinophilic folliculitis and follicular mucinosis. Dermatology. 1998;197(2):178-80. [Medline].

  31. Downs AM, Lear JT, Oxley JD, et al. AIDS associated eosinophilic folliculitis which responded to both high dose co-trimoxazole and low dose isotretinoin. Sex Transm Infect. Jun 1998;74(3):229-30. [Medline].

  32. Ellis E, Scheinfeld N. Eosinophilic pustular folliculitis: a comprehensive review of treatment options. Am J Clin Dermatol. 2004;5(3):189-97. [Medline].

  33. Ho MH, Chong LY, Ho TT. HIV-associated eosinophilic folliculitis in a Chinese woman: a case report and a survey in Hong Kong. Int J STD AIDS. Aug 1998;9(8):489-93. [Medline].

  34. Jang KA, Chung ST, Choi JH, et al. Eosinophilic pustular folliculitis (Ofuji's disease) in myelodysplastic syndrome. J Dermatol. Nov 1998;25(11):742-6. [Medline].

  35. Keida T, Hayashi N, Kawashima M. Eosinophilic pustular folliculitis following autologous peripheral blood stem-cell transplantation. J Dermatol. Jan 2004;31(1):21-6. [Medline].

  36. Lee JY, Tsai YM, Sheu HM. Ofuji's disease with follicular mucinosis and its differential diagnosis from alopecia mucinosa. J Cutan Pathol. May 2003;30(5):307-13. [Medline].

  37. Lucky AW, Esterly NB, Heskel N, et al. Eosinophilic pustular folliculitis in infancy. Pediatr Dermatol. Jan 1984;1(3):202-6. [Medline].

  38. Majors MJ, Berger TG, Blauvelt A, et al. HIV-related eosinophilic folliculitis: a panel discussion. Semin Cutan Med Surg. Sep 1997;16(3):219-23. [Medline].

  39. Ota M, Shimizu T, Hashino S, et al. Eosinophilic folliculitis in a patient after allogeneic bone marrow transplantation: case report and review of the literature. Am J Hematol. Jul 2004;76(3):295-6. [Medline].

  40. Piantanida EW, Turiansky GW, Kenner JR, et al. HIV-associated eosinophilic folliculitis: diagnosis by transverse histologic sections. J Am Acad Dermatol. Jan 1998;38(1):124-6. [Medline].

  41. Ramdial PK, Morar N, Dlova NC, et al. HIV-associated eosinophilic folliculitis in an infant. Am J Dermatopathol. Jun 1999;21(3):241-6. [Medline].

  42. Shirafuji Y, Matsuura H, Sato A, et al. Hyperimmunoglobin E syndrome: a sign of TH1/TH2 imbalance?. Eur J Dermatol. Mar 1999;9(2):129-31. [Medline].

  43. Soeprono FF, Schinella RA. Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome. Report of three cases. J Am Acad Dermatol. Jun 1986;14(6):1020-2. [Medline].

 
Previous
Next
 
Eosinophilic pustular folliculitis in a patient infected with HIV. Note acneiform hyperpigmented papules. Photograph courtesy of Sarah A. Myers, MD.
Eosinophilic pustular folliculitis in a patient who is HIV-positive. Note follicular-based excoriated papules and pustules on the trunk. Photograph courtesy of Sarah A. Myers, MD.
Eosinophilic folliculitis (low-power). Note eosinophilic spongiosis, particularly involving the infundibular region of the hair follicle.
Eosinophilic folliculitis (high-power). In addition to the abundant eosinophils, note the variable numbers of neutrophils and mononuclear cells.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.